Clinical trials: Active Population
Psoriatic Arthritis
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
- Trial name
- NCT02798211
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 258 people
- Sponsor
- Novartis Pharmaceuticals
Contraception
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
The objective of the study is to compare the oral contraceptive (OC) SH T00658ID over Ortho Tri-Cyclen Lo administered for 13 cycles to healthy female volunteers between 18 and 50 years of age who request oral contraceptive…
- Trial name
- NCT00754065
- Testing
- Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
- Where
- 59 sites in United States, Canada
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- Bayer
Acne Vulgaris
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled (clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to demonstrate the efficacy of GSK2585823…
- Trial name
- NCT01445301
- Testing
- GSK2585823(CLDM 1%-BPO 3% gel), CLDM 1% gel twice daily
- Where
- 26 sites in Japan
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are…
- Trial name
- CULTIVATE (NCT04173273)
- Testing
- Etrasimod
- Where
- 510 sites in United States, Argentina and 39 more
- Volunteers
- 379 people
- Sponsor
- Pfizer
Chronic Disease
Measuring the Implementation of the LiFE Program in Primary Care for Older Adults Aged 75 Years or Older
The goal of this study is to evaluate how to implement an evidence-based lifestyle-integrated strength and balance exercise (LiFE) intervention in primary care to promote increased physical activity (PA) and improvements in…
- Trial name
- Mi-LIFE (NCT02266225)
- Testing
- Lifestyle-integrated Functional Exercise
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with RMS.
- Trial name
- NCT04032158
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Anthrax
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine. The vaccine schedule and dose will also be assessed.
- Trial name
- NCT01770743
- Testing
- AV7909, BioThrax
- Where
- 4 sites in United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.
- Trial name
- NCT01089127
- Testing
- Indacaterol, Salmeterol 50 μg
- Where
- 69 sites in United States
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
- Trial name
- PsOsim (NCT02489227)
- Testing
- CHS-1420, Adalimumab
- Where
- 99 sites in United States, Bulgaria and 14 more
- Volunteers
- 545 people
- Sponsor
- Coherus Oncology, Inc.
Uterine Myomas
PGL4001 Versus GnRH-agonist in Uterine Myomas
This trial will assess the efficacy and safety of PGL4001 versus GnRH agonist, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.
- Trial name
- PEARLII (NCT00740831)
- Testing
- PGL4001, leuprorelin
- Where
- 46 sites in Austria, Belgium and 7 more
- Volunteers
- 301 people
- Sponsor
- PregLem SA
Crohn's Disease, IBD
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or…
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Trial name
- NCT01369329
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 175 sites in United States, Australia and 21 more
- Volunteers
- 769 people
- Sponsor
- Janssen Research & Development, LLC
Abdominal Pain
Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort
In contrast with Hyoscine Butylbromide Capsule 10mg, Study is to evaluate the efficacy and safety of Hyoscine Butylbromide tablets 10 mg (20mg, 3 times daily, orally) over a period of 3 days for the treatment of occasional or…
- Trial name
- NCT02242305
- Testing
- Hyoscine Butylbromide - Tablet, Hyoscine Butylbromide - Capsule
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with…
- Trial name
- NCT01606761
- Testing
- Sirukumab
- Where
- 201 sites in United States, Argentina and 20 more
- Volunteers
- 878 people
- Sponsor
- Janssen Research & Development, LLC
Type II Diabetes Mellitus
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients
- Trial name
- NCT01020123
- Testing
- AZD1656, Glipizide
- Where
- 77 sites in Chile, Germany and 9 more
- Volunteers
- 530 people
- Sponsor
- AstraZeneca
Parkinson Disease
Nilotinib in Parkinson's Disease
This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.
- Trial name
- NILO-PD (NCT03205488)
- Testing
- Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
- Where
- 24 sites in United States
- Volunteers
- 76 people
- Sponsor
- Northwestern University
Duchenne Muscular Dystrophy
A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Brief Summary: This Phase IIb study is a randomized, double-blind, parallel group, placebo and active-controlled study to evaluate the efficacy, safety, PD, and population PK of vamorolone administered orally at daily doses of…
- Trial name
- NCT03439670
- Testing
- Vamorolone, Prednisone
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 121 people
- Sponsor
- ReveraGen BioPharma, Inc.
Postmenopausal Osteoporosis
A Study of Monthly Risedronate for Osteoporosis
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
- Trial name
- NCT00247273
- Testing
- risedronate
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 1,294 people
- Sponsor
- Warner Chilcott
Opioid Use Disorders
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and…
- Trial name
- NCT02651584
- Testing
- CAM2038 SC injection, SL BPN/NX tabs
- Where
- 36 sites in United States
- Volunteers
- 428 people
- Sponsor
- Braeburn Pharmaceuticals
Malaria, Vivax
Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
The purpose of this two part study is to test the safety and efficacy of Tafenoquine (with Cholorquine) as a radical cure for Plasmodium vivax (P.vivax) malaria relative to the control Chloroquine.Part 1 aims to select an…
- Trial name
- NCT01376167
- Testing
- Chloroquine 600mg, Chloroquine 300mg, Tafenoquine 50mg
- Where
- 14 sites in Bangladesh, Brazil and 6 more
- Volunteers
- 851 people
- Sponsor
- GlaxoSmithKline
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals